Overview

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)

Status:
Completed

Trial end date:
2021-02-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to explore the safety, preliminary clinical benefit, and activity of BIVV009 in patients with chronic immune thrombocytopenia.

Phase:

Phase 1

Details

Lead Sponsor:

Bioverativ, a Sanofi company
True North Therapeutics